Table 2. Revised tool to assess RoB in randomized trials (RoB 2.0).

Study Name	Year	Randomization Bias	Intervention Deviation	Missing Outcome Data	Measurement of Outcome	Reporting of Outcome	Overall Risk
EXCLAIM	2010	Low	Low	Some Concern	Low	Low	Low
ADOPT	2011	Low	Low	Some Concern	Low	Low	Low
MAGELLAN	2013	Low	Low	Some Concern	Low	Low	Low
APEX	2016	Low	Low	Some Concern	Low	Low	Low
MARINER	2018	Low	Low	Low	Low	Low	Low

Abbreviations: ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, Acute Medically Ill Venous Prevention with Extended Duration Betrixaban; EXCLAIM, Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization; MAGELLAN, Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin; MARINER, Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk; RoB, risk of bias.